Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
AstraZeneca PLC
AZN
$156.58
Name : AstraZeneca PLC
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $242,840,813,568.00
EPSttm : 6.69
finviz dynamic chart for AZN
AstraZeneca PLC
$156.58
0.20%
$0.32
AZN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

0.14

Margin Of Safety %

16

Put/Call OI Ratio

0.57

EPS Next Q Diff

EPS Last/This Y

3.49

EPS This/Next Y

1.49

Price

156.9

Target Price

219.33

Analyst Recom

1.2

Performance Q

-17.49

Upside

-6.2%

Beta

0.33

Ticker: AZN




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-09-08AZN160.030.601.10108206
2026-09-09AZN156.920.610.19110548
2026-09-10AZN160.270.600.14112075
2026-09-11AZN160.150.580.53114483
2026-09-14AZN163.730.580.44115676
2026-09-15AZN161.830.580.31116245
2026-09-16AZN162.710.580.43115823
2026-09-17AZN166.120.580.14115766
2026-09-18AZN166.280.570.05116837
2026-09-21AZN168.080.501.0995247
2026-09-22AZN168.350.530.6099519
2026-09-23AZN163.360.543.62100856
2026-09-24AZN164.510.561.14101823
2026-09-25AZN166.610.560.82102674
2026-09-28AZN166.290.576.08104173
2026-09-29AZN164.250.572.44104241
2026-09-30AZN161.480.581.19105994
2026-10-01AZN157.680.580.37107924
2026-10-02AZN156.880.570.48109665
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-09-08AZN160.01- 6040.710.05
2026-09-09AZN156.91- 5843.510.05
2026-09-10AZN159.62- 7182.610.05
2026-09-11AZN160.21- 7066.210.05
2026-09-14AZN163.73- 7106.710.05
2026-09-15AZN161.83- 6267.010.05
2026-09-16AZN161.83- 6267.010.05
2026-09-17AZN166.12- 6870.810.05
2026-09-18AZN166.29- 6565.510.05
2026-09-21AZN168.08- 6695.510.05
2026-09-22AZN168.41- 3318.410.09
2026-09-23AZN163.36- 5836.010.09
2026-09-24AZN164.59- 6366.010.09
2026-09-25AZN166.61- 6788.710.09
2026-09-28AZN166.32- 6312.210.09
2026-09-29AZN164.23- 6124.610.09
2026-09-30AZN161.50- 6034.610.09
2026-10-01AZN157.69- 5912.410.09
2026-10-02AZN156.90- 6249.110.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-09-08AZN-0.02-0.960.13
2026-09-09AZN-0.02-0.960.13
2026-09-10AZN-0.02-0.960.13
2026-09-11AZN-0.02-0.960.19
2026-09-14AZN-0.02-1.060.19
2026-09-15AZN-0.02-1.060.19
2026-09-16AZN-0.02-1.060.19
2026-09-17AZN-0.02-1.060.19
2026-09-18AZN-0.02-1.060.19
2026-09-21AZN-0.02-1.030.19
2026-09-23AZN-0.02-1.030.19
2026-09-24AZN-0.02-1.030.19
2026-09-25AZN-0.02-1.030.14
2026-09-28AZN-0.02-1.020.14
2026-09-29AZN-0.02-1.020.14
2026-09-30AZN-0.02-1.020.14
2026-10-01AZN-0.02-1.020.14
2026-10-02AZN-0.02-1.020.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS​

2.63

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

-0.02

Institutional Transactions

-1.02

Beta

0.33

Average Sales Estimate Current Quarter

16074

Average Sales Estimate Next Quarter

16702

Fair Value

181.63

Quality Score

93

Growth Score

95

Sentiment Score

15

Actual DrawDown %

26.2

Max Drawdown 5-Year %

-28.7

Target Price

219.33

P/E

23.45

Forward P/E

13.66

PEG

1.16

P/S

3.97

P/B

4.84

P/Free Cash Flow

22.39

EPS

6.69

Average EPS Est. Cur. Y​

10.09

EPS Next Y. (Est.)

11.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

17.02

Relative Volume

0.78

Return on Equity vs Sector %

-5.4

Return on Equity vs Industry %

-14.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

6249.1
◆ AZN Healthcare
$156.91
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
12/20
Pullback
23/25
Volume
9/15
Valuation
18/20
TP/AR
2/10
Options
4/10
RSI
37.9
Range 1M
4.3%
Sup Dist
0.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
30 /100
WEAK
Momentum
4/25
Growth
14/30
Estimates
6/20
Inst/Vol
0/15
Options
6/10
EPS Yr
12.2%
EPS NY
11.8%
52W%
6%
💎
Long-Term Value
Quality companies, undervalued
57 /100
WATCH
🟢 BUY +43.9% upside
Quality
21/30
Valuation
17/30
Growth
11/25
Stability
4/10
LT Trend
4/5
Upside
+43.9%
Quality
93
MoS
16%
AZN — P/E HistoricalDrug Manufacturers - General
AstraZeneca PLC
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 96100
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN

Latest News

—
Caricamento notizie per AZN…
stock quote shares AZN – AstraZeneca PLC Stock Price stock today
news today AZN – AstraZeneca PLC stock forecast ,stock prediction 2023 2024 2025
marketwatch AZN – AstraZeneca PLC yahoo finance google finance
stock history AZN – AstraZeneca PLC invest stock market
stock prices AZN premarket after hours
ticker AZN fair value insiders trading